Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortiumBastian Neesgaard, Lene Ryom, Alain Volny Anne et al.|The Lancet HIV|2022Cited by 140
Recent abacavir use and incident cardiovascular disease in contemporary-treated people with HIVNadine Jaschinski, Lene Ryom, Lauren Greenberg et al.|AIDS|2022Cited by 38
Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaborationNikos Pantazis, Caroline Sabin, Sophie Grabar et al.|The Lancet HIV|2024Cited by 24
Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort StudyHortensia Álvarez, Amanda Mocroft, Lene Ryom et al.|Clinical Infectious Diseases|2023Cited by 23
Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment–Experienced People Living With Human Immunodeficiency VirusLauren Greenberg, H Appoyer, Lene Ryom et al.|Clinical Infectious Diseases|2020Cited by 22